标题
CDK9 inhibitors in acute myeloid leukemia
作者
关键词
Acute myeloid leukemia, CDK9 inhibitor, Positive transcription elongation factor b, P-TEFb, <em class=EmphasisTypeItalic >MCL-1</em>, <em class=EmphasisTypeItalic >MYC</em>
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-02-23
DOI
10.1186/s13046-018-0704-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies
- (2017) Øystein Bruserud et al. Expert Opinion on Drug Discovery
- CDK9: A key player in cancer and other diseases
- (2017) Lia Carolina Franco et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
- (2017) Ranjan Bista et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
- (2016) Shao Xie et al. ACTA PHARMACOLOGICA SINICA
- Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
- (2016) Arne Scholz et al. CANCER RESEARCH
- Overview of CDK9 as a target in cancer research
- (2016) Fatima Morales et al. CELL CYCLE
- Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells
- (2016) Yuanmei Zhai et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
- (2016) Yogesh A. Sonawane et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
- (2016) Tinghu Zhang et al. Nature Chemical Biology
- Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
- (2016) Monica Pallis et al. Oncotarget
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- Abstract 3400: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL1 dependency in responder bone marrow
- (2015) Elisha J. Dettman et al. CANCER RESEARCH
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2015) Ryan D. Cassaday et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
- (2015) S G T Devaraj et al. LEUKEMIA
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
- (2015) Joshua F. Zeidner et al. LEUKEMIA RESEARCH
- Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study
- (2015) Hai-Xiao Jin et al. PLoS One
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
- (2015) Elisabeth Walsby et al. Oncotarget
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
- (2014) Chun-Hao Huang et al. GENES & DEVELOPMENT
- Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
- (2014) William E. Pierceall et al. LEUKEMIA RESEARCH
- A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
- (2014) T. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
- (2014) Gaëlle Mariaule et al. MOLECULES
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
- (2013) D. Thomas et al. BLOOD
- Outcome of older patients with acute myeloid leukemia
- (2013) Mya S. Thein et al. CANCER
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
- (2013) Ivana Gojo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Super-Enhancers in the Control of Cell Identity and Disease
- (2013) Denes Hnisz et al. CELL
- BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
- (2013) W. E. Pierceall et al. MOLECULAR CANCER THERAPEUTICS
- HEXIM1, a New Player in the p53 Pathway
- (2013) Qiao Lew et al. Cancers
- The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells
- (2012) Monica Pallis et al. BRITISH JOURNAL OF HAEMATOLOGY
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
- (2012) Victoria Del Gaizo Moore et al. CANCER LETTERS
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
- (2012) J. E. Karp et al. HAEMATOLOGICA
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
- (2011) J. E. Karp et al. BLOOD
- CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol
- (2011) Xiangrui Liu et al. INTERNATIONAL JOURNAL OF CANCER
- TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
- (2011) K C Goh et al. LEUKEMIA
- The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
- (2011) E Walsby et al. LEUKEMIA
- Flavopiridol inducesBCL-2expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia
- (2011) Dwella M. Nelson et al. LEUKEMIA & LYMPHOMA
- 55K isoform of CDK9 associates with Ku70 and is involved in DNA repair
- (2010) Hongbing Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases
- (2010) Gaetano Romano et al. CELL CYCLE
- Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
- (2010) Zhifu Xiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
- (2009) Rong Chen et al. BLOOD
- CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3′-end processing
- (2009) Judith Pirngruber et al. EMBO REPORTS
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
- (2009) Judith E. Karp et al. LEUKEMIA RESEARCH
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia
- (2009) Dorothee Mueller et al. PLOS BIOLOGY
- The multi-tasking P-TEFb complex
- (2008) Vanessa Brès et al. CURRENT OPINION IN CELL BIOLOGY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started